Humana Investigated Over Securities Fraud Allegations
News related to:Humana Inc · 2 min read
SAN FRANCISCO, Oct. 6, 2026 /CourierPR/ -- Humana Inc., the healthcare services company listed on the New York Stock Exchange (NYSE: HUM), has found itself in the spotlight after a court ruling that allowed key claims in a securities fraud lawsuit against the company and its former CEO and CFO to move forward. The lawsuit alleges that Humana misled investors between July 2022 and October 2024 regarding its exposure to rising costs as patients returned for medical care after the pandemic, causing its stock to trade at artificially inflated prices. U.S. District Judge Jennifer L. Hall found the complaint sufficiently alleged that defendants acted with an intent to defraud in making false and misleading statements. During this period, insiders sold over $104 million in stock. When the truth was fully revealed in October 2024 and Humana reported sharp declines in many of its plans' Star ratings, the stock price fell 22%.
Schubert Jonckheer & Kolbe LLP, a law firm representing consumers in class actions and shareholders in derivative actions against corporate officers and directors, is investigating potential wrongdoing by Humana's directors and officers in connection with these allegations. The firm is encouraging current shareholders to contact them at www.classactionlawyers.com/humana to learn more about their legal options.
We are investigating potential wrongdoing by Humana's directors and officers in connection with these allegations. If you own Humana stock, you may have legal options. Visit www.classactionlawyers.com/humana to learn more.
Humana Inc., a healthcare services company listed on the New York Stock Exchange (NYSE: HUM), has found itself in the spotlight after a court ruling allowed key claims in a securities fraud lawsuit against the company and its former CEO and CFO to move forward. The lawsuit alleges that Humana misled investors between July 2022 and October 2024 regarding its exposure to rising costs as patients returned for medical care after the pandemic, causing its stock to trade at artificially inflated prices. U.S. District Judge Jennifer L. Hall found the complaint sufficiently alleged that defendants acted with an intent to defraud in making false and misleading statements. During this period, insiders sold over $104 million in stock. When the truth was fully revealed in October 2024 and Humana reported sharp declines in many of its plans' Star ratings, the stock price fell 22%.
Schubert Jonckheer & Kolbe LLP, a law firm representing consumers in class actions and shareholders in derivative actions against corporate officers and directors, is investigating potential wrongdoing by Humana's directors and officers in connection with these allegations. The firm is encouraging current shareholders to contact them at www.classactionlawyers.com/humana to learn more about their legal options.
We are investigating potential wrongdoing by Humana's directors and officers in connection with these allegations. If you own Humana stock, you may have legal options. Visit www.classactionlawyers.com/humana to learn more.
Schubert Jonckheer & Kolbe LLP, a law firm representing consumers in class actions and shareholders in derivative actions against corporate officers and directors, is investigating potential wrongdoing by Humana's directors and officers in connection with these allegations. The firm is encouraging current shareholders to contact them at www.classactionlawyers.com/humana to learn more about their legal options. If you own Humana stock, you may have legal options. Visit www.classactionlawyers.com/humana to learn more.